Current Atherosclerosis Reports

Papers
(The H4-Index of Current Atherosclerosis Reports is 29. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
Revascularization Options for Left Main Disease: What Clinicians Need to Know130
Are Clinicians Aggressive Enough in Treating Diabetes-Related Hyperlipidemia in Youth?77
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2024 American Heart Association Scientific Sessions76
Whether and Why Do We Need a Vaccine Against Atherosclerosis? Can We Expect It Anytime Soon?76
Polysocial Risk Scores: Implications for Cardiovascular Disease Risk Assessment and Management66
The Greatly Under-Represented Role of Smooth Muscle Cells in Atherosclerosis60
A Narrative Review of the Association Between Depression and Heart Disease Among Women: Prevalence, Mechanisms of Action, and Treatment59
Heart Transplant, Kawasaki Disease, and Bone Marrow Transplant: Are There Consequences?53
PCSK9 Inhibition and Risk of Diabetes: Should We Worry?52
Glucagon-Like Peptide 1 Receptor Agonists: A Medication for Obesity Management51
The Effects of FABP4 on Cardiovascular Disease in the Aging Population50
Ambient Air Pollution and Atherosclerosis: Recent Updates48
Watermelon and l-Citrulline in Cardio-Metabolic Health: Review of the Evidence 2000–202047
From ‘Omics to Multi-omics Technologies: the Discovery of Novel Causal Mediators47
Myocardial Infarction in the Absence of Obstructive Coronary Artery Disease (MINOCA): a Review of the Present and Preview of the Future46
Polypharmacy and Cardiovascular Diseases: Consideration for Older Adults and Women44
Expanding Biology of PCSK9: Roles in Atherosclerosis and Beyond40
Genetic Testing for Familial Hypercholesterolemia in Clinical Practice39
DOACs and Atherosclerotic Cardiovascular Disease Management: Can We Find the Right Balance Between Efficacy and Harm38
The Genetic Basis of Hypertriglyceridemia37
Programmable Genome-Editing Technologies as Single-Course Therapeutics for Atherosclerotic Cardiovascular Disease36
Inflammation in the Peri-ACS Period: Ready for Prime Time?34
The Emerging Specialty of Cardio-Rheumatology34
Percutaneous Coronary Interventions in Women33
Correction to: Beta‑blockers for Atherosclerosis Prevention: a Missed Opportunity?32
Lipid Lowering Therapy Utilization and Lipid Goal Attainment in Women30
The Role of Non-Statin Lipid Lowering Therapies to Reduce ASCVD Events in Primary Prevention30
Nutrition Interventions for Youth with Dyslipidemia: Who, What, When, and Where?30
Lipoprotein(a): from Causality to Treatment29
The Intersection Between COVID-19, Cardiovascular Disease, and Diet: a Review29
RNA Silencing in the Management of Dyslipidemias29
Myeloid Cells in Abdominal Aortic Aneurysm29
GLP-1 Receptor Agonists and Cardiovascular Disease: What Do Clinicians Need to Know?29
0.022834062576294